Mesothelioma Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Mesothelioma remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 232 matched trial records and 566 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07602946 | Navlimetostat | Phase 2; Not yet recruiting | The University of Southampton | United Kingdom | SELECTmeso Platform : Molecular profiling of participant's tumour block SELECTmeso1: Disease Control Rate (DCR) using RECIST 1.1 at 12 weeks. (SELECTmeso Platform: Baseline SELECTmeso1: at 12 weeks of treatment) | 2027-07-01 |
| NCT07563738 | Ipilimumab + Nivolumab + Albumin-Bound Paclitaxel | Phase 1/2; Recruiting | Sponsor not listed | United States | Incidence of Dose Limiting Toxicities and Adverse Events (Through study completion, on average of 2 years) | 2029-09-01 |
| NCT07561190 | Intervention not normalized | Not Applicable; Recruiting | Azienda Unità Sanitaria Locale di Reggio Emilia | Italy | High-resolution mapping of the organization of the tumor-infiltrating immune system in MPM (36 months) | 2024-08-30 |
| NCT07550049 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Kansas Medical Center | Geography not listed | Establish a comprehensive blood and tissue biobank (Samples will be collected at baseline (prior to treatment), over four cycles…) | 2029-04-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (Phase 1/2): the indexed record reports -; -; -.
- Efficacy and safety of immune checkpoint inhibitors after platinum-based therapy for refractory or recurrent malignant pleural mesothelioma: A systematic review and meta-analysis. (Not Applicable): the indexed record reports ORR = 25.3 % ( 17.1 - 35.7); ORR = 11.0 % ( 6.7 - 17.5).
- Combining immune checkpoint inhibition and dendritic cell vaccination in advanced pleural and peritoneal mesothelioma: The phase 1b MESOVAX trial. (Phase 1): the indexed record reports TRAE = Treatment-related adverse events (TRAEs) of any grade occurred in all 9 pts, with the most frequent being injection site reactions, asthenia, and fever. No grade 3-4 TRAEs were reported.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Navlimetostat (Phase 2/3; MTA-PRMT5), Ipilimumab (Approved; CTLA4), Nivolumab (Approved; PD-1), Albumin-Bound Paclitaxel (Approved; Tubulin). Company & Deal Intelligence records identify sponsor context for The University of Southampton, Azienda Unità Sanitaria Locale di Reggio Emilia, University of Kansas Medical Center. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Mesothelioma has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
